Showing results (191-200 of 212) with videos related to

Sort By:
Pageof 22
Molecular Oncology|April 27, 2020
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumorsXi Yuan, Zhiyu Tang, Rong Du, et al.
Nature Communications|November 16, 2019
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsMatthew J Sale, Emma Minihane, Noel R Monks, et al.
The Journal of Biological Chemistry|July 28, 2009
Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidateMatthew L Plassmeyer, Karine Reiter, Richard L Shimp, et al.
Nature Immunology|November 24, 2020
MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effectsVivek Verma, Nazli Jafarzadeh, Shannon Boi, et al.
NPJ Precision Oncology|December 27, 2022
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSteven W Criscione, Matthew J Martin, Derek B Oien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2012
Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft modelsJingchuan Zhang, Lin Zhang, Xinying Su, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 6, 2019
Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencingD Gareth Evans, Claire L Hartley, Philip T Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancerUdai Banerji, D Ross Camidge, Henk M W Verheul, et al.
Cancer Research|October 10, 2014
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanomaY N Vashisht Gopal, Helen Rizos, Guo Chen, et al.
Molecular Cancer Therapeutics|November 16, 2014
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxelUrs Hancox, Sabina Cosulich, Lyndsey Hanson, et al.
Pageof 22